Welcome to our dedicated page for Microbix Biosys news (Ticker: MBXBF), a resource for investors and traders seeking the latest updates and insights on Microbix Biosys stock.
Microbix Biosystems Inc. (MBXBF) is a life sciences innovator, manufacturer, and exporter that focuses on biological products for the global diagnostics industry. News about Microbix often centers on developments in its antigen manufacturing capabilities, expansion of its quality assessment products (QAPs™), and updates on its reference materials (QUANTDx™) used by clinical laboratories and diagnostics makers.
Investors and industry professionals following Microbix news can expect updates on product commercialization, such as the company’s recombinant nucleocapsid antigen of the SARS-CoV-2 virus for use in QAPs and by test manufacturers. Coverage may also include announcements related to its expertise in native viral antigens, new applications of its QAPs and reference materials in proficiency testing and external quality assessment programs, and developments in reagents and media that support diagnostic testing, including DxTM™ for patient-sample collection.
Microbix news releases also address regulatory and disclosure matters, including interactions with securities regulators about continuous disclosure practices and the use of non-IFRS financial measures. These items provide context about how the company presents its financial and operational information to investors.
Because Microbix supplies antigens to approximately 100 diagnostics makers and distributes QAPs in over 30 countries, its news can be relevant to stakeholders across the diagnostics value chain. By monitoring this page, readers can review announcements about product launches, manufacturing capabilities, quality and regulatory accreditations, and other corporate communications that shape the company’s role in the diagnostics and life sciences sectors.
Microbix (TSX:MBX / OTCQX:MBXBF) announced the issuance of 2,600,000 stock options under its shareholder-approved Stock Option Plan on February 24, 2026. Options are exercisable at $0.23 per share, vest after three years, and expire after five years; grants are subject to TSX approval.
The awards span 37 senior employees and directors, with a quarterly expense estimate of $24,000 (≈2% of total compensation). Potential dilution is stated as up to 2% of issued shares, partly offset by ~600,000 shares repurchased under a normal-course issuer bid started December 2025.
Microbix (OTCQX:MBXBF) reported Q1 fiscal 2026 results for the quarter ended December 31, 2025, with revenue of $4.22M (down 30% YoY, up 13% QoQ) and a net loss of $1.17M. Gross margin fell to 41% from 62% a year earlier. Cash was $9.10M and accounts receivable rose to $3.98M. Management expects full‑year results in line with disclosed forward‑looking information and is pursuing new clients and programs; a Q1 webinar is scheduled for February 12, 2026 at 10:00 AM ET.
Microbix (OTCQX:MBXBF) has begun supplying its quality assessment products (QAPs) to the College of American Pathologists (CAP) to support CAP proficiency-testing (PT/EQA) programs as of February 10, 2026. Multiple QAP SKUs have been provided under customary supply and quality agreements, and Microbix plans expansion through fiscal 2026.
The QAPs are designed to emulate patient specimens while remaining safe and stable, supporting diagnostic workflows and ISO 17043-certified PT/EQA programs.
Microbix (OTCQX:MBXBF, TSX:MBX) will release financial results for its first quarter of fiscal 2026 (period ended December 31, 2025) prior to market open on February 12, 2026. A live webinar discussion with CEO, CFO and COO is scheduled for 10:00 AM ET that day and will be hosted by Adelaide Capital.
Investors can register via Zoom and watch a YouTube livestream; a replay will be posted on Adelaide Capital's YouTube channel.
Microbix (TSX:MBX, OTCQX:MBXBF) will present results of its novel Quality Assessment Products (QAPs™) and FFPE-simulated platform at Labquality Days in Helsinki on February 5–6, 2026. The poster shows a reproducible platform creating homogeneous, stable QC materials suitable across molecular pathology methods and instruments, demonstrated for HPV, HSV, and Chlamydia trachomatis. Microbix acknowledges collaborators including Dartmouth-Hitchcock, Hvidovre Hospital, Abbott Molecular, Cardiogenics, and QuidelOrtho. The poster will be posted on the Microbix website and purchase enquiries can be emailed to customer.service@microbix.com.
Microbix (OTCQX:MBXBF, TSX:MBX) updated its investor presentation on January 9, 2026 to add disclosures on its use of EBITDA after receiving comments from staff of the Ontario Securities Commission (OSC). OSC staff flagged two slides that used EBITDA without the required National Instrument 52-112 disclosures: the composition of the non-GAAP measure, how it helps investors, and a quantitative reconciliation to the most directly comparable IFRS measure. The company revised its fiscal Q3 2025 investor presentation to include the additional non-GAAP disclosure. The updated presentation is available from Microbix's investors page at https://microbix.com or https://microbix.com/presentations.
Microbix (OTCQX:MBXBF) announced commercial availability of its first internally manufactured SARS-CoV-2 recombinant nucleocapsid antigen on January 7, 2026.
The antigen is fully validated, produced at commercial scale, is now used in Microbix QAPs and incorporated into PROCEEDx (RUO) and REDx (IVD) branded quality assessment products. Microbix reported QAP sales totaled C$5.6 million in fiscal 2025. In-house recombinant production is cited to improve supply-chain security and cost control.